Bronchopulmonary dysplasia—A historical perspective
Corresponding Author
Julian Allen MD
Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Correspondence Julian Allen, MD, Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, 34th St and Civic Ctr Blvd, Colket 11, Philadelphia, PA 19104, USA.
Email: [email protected]
Search for more papers by this authorHoward Panitch MD
Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Search for more papers by this authorCorresponding Author
Julian Allen MD
Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Correspondence Julian Allen, MD, Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, 34th St and Civic Ctr Blvd, Colket 11, Philadelphia, PA 19104, USA.
Email: [email protected]
Search for more papers by this authorHoward Panitch MD
Division of Pulmonary and Sleep Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
Search for more papers by this authorAbstract
Bronchopulmonary dysplasia (BPD) was first described by Northway et al in 1967. This article describes the evolution of our understanding of the pathophysiology of BPD and the approaches to treatments of this illness developed over the past fifty years. These interventions had their roots in the understanding of the principles of the surface tension present at air–liquid interfaces, which were developed over 150 years before BPD's initial description. Improving outcomes in neonatal care have led to greater survival of preterm and very preterm infants, and to an evolution of the pathogenesis and pathology of BPD, from an illness caused primarily by barotrauma and oxygen toxicity to one of interruption of lung development. While the incidence of BPD has remained about the same in recent decades, this is because survival of infants born at lower gestational ages is increasing. Understanding of molecular, genetic and physiologic mechanisms has led to newer treatments that have mitigated some of the harmful effects of prolonged mechanical ventilation. Recognition of BPD as a chronic multi-system disease has resulted in further improvements in care after discharge from neonatal intensive care. Since many of the origins of chronic obstructive lung disease in adults are based in childhood respiratory illnesses, improving outcomes of BPD in infancy and childhood will undoubtedly lead to improved respiratory outcomes in the adults that these children will become.
REFERENCES
- 1Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276(7): 357-368.
- 2Philip AG. Chronic lung disease of prematurity: a short history. Semin Fetal Neonatal Med. 2009; 14(6): 333-338.
- 3Young T. An essay on the cohesion of fluids. Philos Trans R Soc London. 1805; 95: 65-87.
- 4Boys C. Soap-Bubbles and the Forces Which Mould Them. Being a Course of Three Lectures Delivered in the Theatre of the London Institution on the Afternoons of Dec. 30, 1889, Jan. 1 and 3, 1890, Before a Juvenile Audience. Society for promoting Christian knowledge; E. & J.B. Young & Co.; 1896.
- 5Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. 1959; 97(5, Part 1): 517-523.
- 6Silverman WA, Fertig JW, Berger AP. The influence of the thermal environment upon the survival of newly born premature infants. Pediatrics. 1958; 22(5): 876-886.
- 7Usher R. Reduction of mortality from respiratory distress syndrome of prematurity with early administration of intravenous glucose and sodium bicarbonate. Pediatrics. 1963; 32: 966-975.
- 8Chase HC, Byrnes ME. Trends in “prematurity”: United States, 1950–1967. Am J Public Health Nations Health. 1970; 60(10): 1967-1983.
- 9Infant, fetal, and maternal mortality United States-. Vital Health Stat 20. 1963; 1966(3): 1-64.
- 10 National Heart, Lung and Blood Institutes. Respiratory distress syndrome: brighter prospects for premature babies. 2011. https://www.nhlbi.nih.gov/news/2011/respiratory-distress-syndrome-brighter-prospects-premature-babies
- 11Berger TM, Fontana M, Stocker M. The journey towards lung protective respiratory support in preterm neonates. Neonatology. 2013; 104(4): 265-274.
- 12Ryan MS. Patrick Bouvier Kennedy: a Brief Life that Changed the History of Newborn Care. MCP Books; 2015.
- 13Wilson MG, Mikity VG. A new form of respiratory disease in premature infants. AMA J Dis Child. 1960; 99: 489-499.
- 14Hawker JM, Reynolds EO, Taghizadeh A. Pulmonary surface tension and pathological changes in infants dying after respirator treatment for severe hyaline membrane disease. Lancet. 1967; 2(7506): 75-77.
- 15DeLemos R, Wolfsdorf J, Nachman R, et al. Lung injury from oxygen in lambs: the role of artificial ventilation. Anesthesiology. 1969; 30(6): 609-618.
- 16Giammona ST, Kerner D, Bondurant S. Effect of oxygen breathing at atmospheric pressure on pulmonary surfactant. J Appl Physiol. 1965; 20(5): 855-858.
- 17Kaplan HP, Robinson FR, Kapanci Y, Weibel ER. Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. I. Clinical and light microscopic studies. Lab Invest. 1969; 20(1): 94-100.
- 18Nash G, Blennerhassett JB, Pontoppidan H. Pulmonary lesions associated with oxygen therapy and artifical ventilation. N Engl J Med. 1967; 276(7): 368-374.
- 19Coalson JJ, Winter VT, Siler-Khodr T, Yoder BA. Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med. 1999; 160(4): 1333-1346.
- 20Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50(4): 515-525.
- 21McCarthy M. US recommendations for antenatal corticosteroids. Lancet. 1994; 343(8899): 726.
- 22Van Marter LJ, Leviton A, Kuban KC, Pagano M, Allred EN. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics. 1990; 86(3): 331-336.
- 23Philip AG. Oxygen plus pressure plus time: the etiology of bronchopulmonary dysplasia. Pediatrics. 1975; 55(1): 44-50.
- 24 National Center for Biotechnology Information. Workshop on bronchopulmonary dysplasia. Sponsored by the Division of Lung Diseases. National Heart, Lung, and Blood Institute, National Institutes of Health. J Pediatr. 1979; 95(5 Pt 2):815920.
- 25Stahlman MT, Malan AF, Shepard FM, Blankenship WJ, Young WC, Gray J. Negative pressure assisted ventilation in infants with hyaline membrane disease. J Pediatr. 1970; 76(2): 174-182.
- 26Mammel MC, Bing DR. Mechanical ventilation of the newborn. An overview. Clin Chest Med. 1996; 17(3): 603-613.
- 27Mushin WW, Mapleson WW, Lunn JN. Problems of automatic ventilation in infants and children. Br J Anaesth. 1962; 34: 514-522.
- 28Kirby R, Robison E, Schulz J, DeLemos RA. Continuous-flow ventilation as an alternative to assisted or controlled ventilation in infants. Anesth Analg. 1972; 51(6): 871-875.
- 29Kirby RR, Robison EJ, Schulz J, DeLemos R. A new pediatric volume ventilator. Anesth Analg. 1971; 50(4): 533-537.
- 30Kirby RR. Intermittent mandatory ventilation in the neonate. Crit Care Med. 1977; 5(1): 18-22.
- 31Avery ME, Tooley WH, Keller JB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics. 1987; 79(1): 26-30.
- 32Gregory GA, Kitterman JA, Phibbs RH, Tooley WH, Hamilton WK. Treatment of the idiopathic respiratory-distress syndrome with continuous positive airway pressure. N Engl J Med. 1971; 284(24): 1333-1340.
- 33Lee KS, Dunn MS, Fenwick M, Shennan AT. A comparison of underwater bubble continuous positive airway pressure with ventilator-derived continuous positive airway pressure in premature neonates ready for extubation. Biol Neonate. 1998; 73(2): 69-75.
- 34Morley CJ, Lau R, De Paoli A, Davis PG. Nasal continuous positive airway pressure: does bubbling improve gas exchange? Arch Dis Child Fetal Neonatal Ed. 2005; 90(4): F343-F344.
- 35Morray JP, Fox WW, Kettrick RG, Downes JJ. Clinical correlates of successful weaning from mechanical ventilation in severe bronchopulmonary dysplasia. Crit Care Med. 1981; 9(12): 815-818.
- 36Pinney MA, Cotton EK. Home management of bronchopulmonary dysplasia. Pediatrics. 1976; 58(6): 856-859.
- 37Philip AG, Peabody JL, Lucey JF. Transcutaneous Po2 monitoring in the home management of bronchopulmonary dysplasia. Pediatrics. 1978; 61(4): 655-657.
- 38Saugstad OD. Oxygen radicals and pulmonary damage. Pediatr Pulmonol. 1985; 1(3): 167-175.
- 39Mishra OP, Delivoria-Papadopoulos M. Lipid peroxidation in developing fetal guinea pig brain during normoxia and hypoxia. Brain Res Dev Brain Res. 1989; 45(1): 129-135.
- 40Saldanha RL, Cepeda EE, Poland RL. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia. J Pediatr. 1982; 101(1): 89-93.
- 41Shenai JP, Kennedy KA, Chytil F, Stahlman MT. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987; 111(2): 269-277.
- 42Fujimura M, Takeuchi T, Kitajima H, Nakayama M. Chorioamnionitis and serum IgM in Wilson-Mikity syndrome. Arch Dis Child. 1989; 64(10 Spec No): 1379-1383.
- 43Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985; 75(1): 106-111.
- 44Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989; 320(23): 1505-1510.
- 45Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983; 1(8338): 1356-1358.
- 46Philip AG. Treatment of bronchopulmonary dysplasia with corticosteroids. Clin Res. 1974; 22: 242.
- 47Massaro D, Teich N, Maxwell S, Massaro GD, Whitney P. Postnatal development of alveoli. Regulation and evidence for a critical period in rats. J Clin Invest. 1985; 76(4): 1297-1305.
- 48Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr. 1978; 92(6): 982-984.
- 49Engelhardt B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1989; 114(4 Pt 1): 619-624.
- 50Kao LC, Warburton D, Sargent CW, Platzker AC, Keens TG. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. J Pediatr. 1983; 103(4): 624-629.
- 51Kao LC, Durand DJ, Phillips BL, Nickerson BG. Oral theophylline and diuretics improve pulmonary mechanics in infants with bronchopulmonary dysplasia. J Pediatr. 1987; 111(3): 439-444.
- 52Frank L, Sosenko IR. Undernutrition as a major contributing factor in the pathogenesis of bronchopulmonary dysplasia. Am Rev Respir Dis. 1988; 138(3): 725-729.
- 53Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet. 1980; 1(8159): 55-59.
- 54Hudak BB, Allen MC, Hudak ML, Loughlin GM. Home oxygen therapy for chronic lung disease in extremely low-birth-weight infants. Am J Dis Child. 1989; 143(3): 357-360.
- 55High-frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants. The HIFI Study Group. N Engl J Med. 1989; 320(2): 88-93.
- 56Sotomayor JL, Godinez RI, Borden S, Wilmott RW. Large-airway collapse due to acquired tracheobronchomalacia in infancy. Am J Dis Child. 1986; 140(4): 367-371.
- 57Cohn RC, Kercsmar C, Dearborn D. Safety and efficacy of flexible endoscopy in children with bronchopulmonary dysplasia. Am J Dis Child. 1988; 142(11): 1225-1228.
- 58Ardell S, Pfister RH, Soll R. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2015; 8:CD000144.
- 59Sardesai S, Biniwale M, Wertheimer F, Garingo A, Ramanathan R. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res. 2017; 81(1-2): 240-248.
- 60Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med. 1993; 328(6): 406-410.
- 61Weaver TE, Whitsett JA. Processing of hydrophobic pulmonary surfactant protein B in rat type II cells. Am J Physiol. 1989; 257(2 Pt 1): L100-L108.
- 62Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med. 2002; 347(26): 2141-2148.
- 63Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics. 2005; 115(4): 1030-1038.
- 64Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999; 46(6): 641-643.
- 65Stocker JT. Pathologic features of long-standing "healed" bronchopulmonary dysplasia: a study of 28 3- to 40-month-old infants. Hum Pathol. 1986; 17(9): 943-961.
- 66Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol. 1998; 29(7): 710-717.
- 67Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics. 2002; 110(1 Pt 1): 143-151.
- 68Abman SH, Kinsella JP. Inhaled nitric oxide therapy of pulmonary hypertension and respiratory failure in premature and term neonates. Adv Pharmacol. 1995; 34: 457-474.
- 69Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Pediatrics. 2011; 128(4): 729-739.
- 70Kotecha S, Allen J. Oxygen therapy for infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002; 87(1): F11-F14.
- 71Supplemental therapeutic oxygen for prethreshold retinopathy Of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000; 105(2): 295-310.
- 72 Group BIUKC, Group BIAC, Group BINZC, Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med. 2013; 368(22): 2094-2104.
- 73 American Thoracic S, European Respiratory S. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med. 2005; 172(11): 1463-1471.
- 74 J Stocks, PD Sly, RS Tepper, WJ Morgan, eds. Infant Respiratory Function Testing. Wiley-Liss, John Wiley & Sons, Inc; 1996.
- 75Panitch HB, Allen JL, Alpert BE, Schidlow DV. Effects of CPAP on lung mechanics in infants with acquired tracheobronchomalacia. Am J Respir Crit Care Med. 1994; 150(5 Pt 1): 1341-1346.
- 76Zinman R. Tracheal stenting improves airway mechanics in infants with tracheobronchomalacia. Pediatr Pulmonol. 1995; 19(5): 275-281.
- 77Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol. 1990; 9(3): 170-176.
- 78Shaffer TH, Alapati D, Greenspan JS, Wolfson MR. Neonatal non-invasive respiratory support: physiological implications. Pediatr Pulmonol. 2012; 47(9): 837-847.
- 79Make BJ, Hill NS, Goldberg AI, et al. Mechanical ventilation beyond the intensive care unit. Report of a consensus conference of the American College of Chest Physicians. Chest. 1998; 113(5 Suppl): 289S-344S.
- 80Panitch HB, Downes JJ, Kennedy JS, et al. Guidelines for home care of children with chronic respiratory insufficiency. Pediatr Pulmonol. 1996; 21(1): 52-56.
10.1002/(SICI)1099-0496(199601)21:1<52::AID-PPUL9>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 81Allen J, Zwerdling R, Ehrenkranz R, et al. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med. 2003; 168(3): 356-396.
- 82Reid L. 1976 Edward BDNeuhauser lecture: the lung: growth and remodeling in health and disease. AJR Am J Roentgenol. 1977; 129(5): 777-788
- 83Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007; 175(10): 978-985.
- 84Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007; 120(6): 1260-1269.
- 85Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009; 154(3): 379-384.
- 86Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology. 2008; 93(4): 284-287.
- 87Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006; 354(20): 2112-2121.
- 88Gower WA, Wert SE, Nogee LM. Inherited surfactant disorders. NeoReviews. 2008; 9: e458-e467.
10.1542/neo.9-10-e458 Google Scholar
- 89Pavlovic J, Papagaroufalis C, Xanthou M, et al. Genetic variants of surfactant proteins A, B, C, and D in bronchopulmonary dysplasia. Dis Markers. 2006; 22(5-6): 277-291.
- 90Bullard JE, Nogee LM. Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res. 2007; 62(2): 176-179.
- 91Nogee LM. Genetic mechanisms of surfactant deficiency. Biol Neonate. 2004; 85(4): 314-318.
- 92Nogee LM. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu Rev Physiol. 2004; 66: 601-623.
- 93Saugstad OD, Hansen TWR, Rønnestad A, et al. Novel mutations in the gene encoding ATP binding cassette protein member A3 (ABCA3) resulting in fatal neonatal lung disease. Acta Paediatr. 2007; 96(2): 185-190.
- 94Abman SH, Mourani PM, Sontag M. Bronchopulmonary dysplasia: a genetic disease. Pediatrics. 2008; 122(3): 658-659.
- 95Bhandari V, Gruen JR. The genomics of bronchopulmonary dysplasia. NeoReviews. 2007; 8: e336-e344.
10.1542/neo.8-8-e336 Google Scholar
- 96Merrill JD, Ballard RA, Cnaan A, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res. 2004; 56(6): 918-926.
- 97Jobe AH. Effects of chorioamnionitis on the fetal lung. Clin Perinatol. 2012; 39(3): 441-457.
- 98Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia. Am J Perinatol. 2016; 33(11): 1076-1078.
- 99Kallapur SG, Kramer BW, Jobe AHU, Semin BPD. Perinatol. 2013; 37(2): 94-101.
- 100Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019; 5(1): 78.
- 101Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (>7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 10:CD001145.
- 102Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 10:CD001146.
- 103Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol. 2009; 36(1): 177-188.
- 104Hwang SS, Burris HH, Collins JW, Jr., Kirpalani H, Wright CJ. Moving beyond race and ethnicity to understand the effect of inhaled nitric oxide on bronchopulmonary dysplasia prevention. J Pediatr. 2018; 201: 298-300.
- 105Kadmon G, Schiller O, Dagan T, Bruckheimer E, Birk E, Schonfeld T. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2017; 52(1): 77-83.
- 106Guaman MC, Gien J, Baker CD, Zhang H, Austin ED, Collaco JM. Point prevalence, clinical characteristics, and treatment variation for infants with severe bronchopulmonary dysplasia. Am J Perinatol. 2015; 32(10): 960-967.
- 107Abman SH, Nelin LD. In: E Bancalari, ed. Management of the Infant with Severe Bronchopulmonary Dysplasia. Elsevier Saunders; 2012: 407-425.
- 108Napolitano N, Jalal K, McDonough JM, et al. Identifying and treating intrinsic PEEP in infants with severe bronchopulmonary dysplasia. Pediatr Pulmonol. 2019; 54(7): 1045-1051.
- 109Eichenwald C, Dysart K, Zhang H, Fox W. Neonatal partial liquid ventilation for the treatment and prevention of bronchopulmonary dysplasia. Neoreviews. 2020; 21(4): e238-e248.
- 110Jobe AH, Steinhorn R. Can we define bronchopulmonary dysplasia? J Pediatr. 2017; 188: 19-23.
- 111Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr. 2018; 197: 300-308.
- 112Jensen EA, Dysart K, Gantz MG, et al. The diagnosis of bronchopulmonary dysplasia in very preterm infants. An evidence-based approach. Am J Respir Crit Care Med. 2019; 200(6): 751-759.
- 113Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7): 1723-1729.
- 114Poindexter BB, Feng R, Schmidt B, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc. 2015; 12(12): 1822-1830.
- 115Tooley WH. Epidemiology of bronchopulmonary dysplasia. J Pediatr. 1979; 95(5 Pt 2): 851-858.
- 116Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979; 95(5 Pt 2): 819-823.
- 117Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988; 82(4): 527-532.
- 118Abman SH, Collaco JM, Shepherd EG, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017; 181: 12-28.
- 119Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA. 2015; 314(10): 1039-1051.
- 120Allen JL. Airway function throughout the lifespan: pediatric origins of adult respiratory disease. Pediatr Investig. 2019; 3(4): 236-244.
- 121Kumar VHS, Wang H, Kishkurno S, Paturi BS, Nielsen L, Ryan RM. Long-term effects of neonatal hyperoxia in adult mice. Anat Rec. 2018; 301(4): 717-726.
- 122Yee M, Chess PR, McGrath-Morrow SA, et al. Neonatal oxygen adversely affects lung function in adult mice without altering surfactant composition or activity. Am J Physiol Lung Cell Mol Physiol. 2009; 297(4): L641-L649.
- 123Bui DS, Burgess JA, Lowe AJ, et al. Childhood lung function predicts adult chronic obstructive pulmonary disease and asthma-chronic obstructive pulmonary disease overlap syndrome. Am J Respir Crit Care Med. 2017; 196(1): 39-46.
- 124McGrath-Morrow SA, Collaco JM. Bronchopulmonary dysplasia: what are its links to COPD? Ther Adv Respir Dis. 2019; 13:1753466619892492.
- 125Sillers L, Alexiou S, Jensen EA. Lifelong pulmonary sequelae of bronchopulmonary dysplasia. Curr Opin Pediatr. 2020; 32(2): 252-260.